ES_cFAQ_IXE375_USE_IN_PATIENTS_WITH_HIDRADENITIS

Información detallada

Ixekizumab no está indicado para el tratamiento de la hidradenitis supurativa.1Por favor, diríjase a la ficha técnica de Taltz para consultar las indicaciones aprobadas de ixekizumab.

Búsqueda bibliográfica

Se ha llevado a cabo una búsqueda bibliográfica el día 31/01/2023 en las bases de datos EMBASE y MEDLINE, usando las palabras clave "hidradenitis supurativa" e "ixekizumab" obteniendo los resultados que puede encontrar a continuación.

La información incluída en esta búsqueda bibliográfica es para responder a su pregunta espontánea sobre información médica. Las referecias y/o abstracts incluídos aparecen tal y como aparecían en dichas bases de datos y no han sido editadas por Lilly más allá que para eliminar duplicados, eliminar abstracts que no puedan ser compartidos por leyes que protejan los derechos de autor o para eliminar publicaciones que no sean relevantes para la questión original.

1. An Anti-Interleukin-17A Monoclonal Antibody, Ixekizumab, in the Treatment of Resistant Hidradenitis Suppurativa: A Case Series

Esme P, Botsali A, Akoglu G, Caliskan E.

Skin Appendage Disorders. 2022.

Abstract: Although adalimumab is the only approved biologic for the treatment of hidradenitis suppurativa (HS), the treatment response may not be satisfactory in all patients. Recently, many other biological agents, including interleukin 17 inhibitors such as ixekizumab, have shown promise. Case Presentations: Five severe HS (Hurley stage III) patients resistant to conventional treatments and adalimumab for at least 3 months were recruited. Patients were prescribed ixekizumab with a scheme approved for psoriasis (160 mg once, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12.) The primary outcome measure was achieving the Hidradenitis Suppurativa Clinical Response (HiSCR) score following 12 weeks. Secondary outcome measures included the patient-reported Dermatology Life Quality Index (DLQI) and visual analog scale (VAS). Four of 5 patients (80%) achieved HiSCR. While improvement was observed in the VAS and DLQI scores of 4 patients, the decline was limited in 1 patient. No adverse event was recorded related to ixekizumab.
Conclusion(s): The result of our observation suggests that ixekizumab may be effective for HS, especially in challenging cases.

2. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine during Ixekizumab treatment for hidradenitis suppurativa

Iannone M, Janowska A, Tonini G, Davini G, Dini V.

Clin Dermatol. 2021 May 19

3. Severe hidradenitis suppurativa with herpes simplex virus 1 superinfection and clinical responsiveness to ixekizumab

Reardon K., Levin J., Levin C.

JAAD Case Rep. 2021 Jan 10;9:7-8

4. Ixekizumab restores clinical response in patients with secondary loss of efficacy from adalimumab: Results of a case series of 10 patients with hidradenitis suppurativa

Hilbring C.; Girbig G.; Augustin M.; Kirsten N.

Experimental Dermatology. Conference: 9th Conference of the European Hidradenitis Suppurativa Foundation. Greece. 29 (SUPPL 1) (pp 33), 2020

Background: An increased expression of inflammatory cytokines such as IL-1beta, TNF-alpha, CXCL9 or IL-17A in lesional skin indicates an immunological genesis of hidradenitis suppurativa (HS) and offers new therapeutic approaches. The objective was to evaluate the effect of IL-17 inhibitor Ixekizumab (Taltz) in patients with HS after being treated according to guidelines with systemic antibiotics and adalimumab. Method(s): We included 10 patients and started treating them with the IL-17 inhibitor Ixekizumab (80 mg/4 weeks), evaluated the response after 4 and 16 weeks of treatment in comparison to baseline. Result(s): We included 10 patients with HS (9 female). The mean age was 38 years. In total average IHS4 score decreased from 13.6 in week 0 to 9.6 in week 16. 3 patients did not respond to treatment. One patient showed a clinical worsening in week 16 after initial improvement in week 4. The mean DLQI also showed a decline from 11.7 in week 0 to 7.8 in week 16. In two patients the DLQI dropped more than 10 points from baseline. Conclusion(s): Further studies are needed to assess the efficacy of Ixekizumab in HS.

5. Ixekizumab: An efficacious treatment for both psoriasis and hidradenitis suppurativa

Megna M.; Ruggiero A.; Di Guida A.; Patri A.; Fabbrocini G.; Marasca C.

Dermatologic Therapy. 33 (4) (no pagination), 2020. Article Number: e13756

6. Hidradenitis suppurativa successfully treated with ixekizumab - presentation of 2 cases

Kirsten N.; Augustin M.

Experimental Dermatology. Conference: 8th European Hidradenitis Suppurativa Foundation Conference, EHSF 2019. Poland. 28 (Supplement 2) (pp 23), 2019

Abstract: Hidradenitis suppurativa is a chronic inflammatory skin disease that leads to a severe loss of quality of life. The disease is often intermittent and characterized by the development of inflammatory nodules, abscesses and draining fistulas. The exact pathogenesis are not yet fully understood, an increased expression of inflammatory cytokines such as IL-1beta, TNF-alpha, CXCL9 or IL-17A in lesional skin indicates an immunological genesis. First case reports on the efficacy of Secukinumab have been published. We report two cases of severe Hidradenitis suppurativa that were successfully treated with Ixekizumab. Case report 1: A 56 year old female patient presented with multiple diffuse fistulas and inflammatory nodules in the area of both groins and genital region (Hurley III, HS-PGA 5, ISH 55) in our Hidradenitis suppurativa consultation. After an antibiotic treatment with clindamycin and rifampicin 300 mg twice daily each, there was a slight improvement in fistula secretion. The patient reacted to the change to Adalimumab with a late type allergic reaction, so that we started a treatment with Guselkumab. As the therapy was not successful after 12 weeks, we switched to Ixekizumab. Already after 8 weeks a clear improvement of the findings was observed with only one active fistula (ISH 4). Case report 2: A 27-year- old female patient presented with mutilating inflammatory foci (fistulas and inflammatory nodules) in both groins and axillae after multiple previous surgeries (Hurley III, HS-PGA 5, ISH 35). After an initial improvement of inflammation under Adalimumab, a secondary loss of efficacy occurred about 9 months after the start of therapy with the occurence of a severely inflamed fistula in the area of the right groin to Mons pubis, so that the treatment was changed to Ixekizumab. After the reduction of the inflammatory reaction, the fistula was surgically removed. Of these, no new inflammatory lesions occurred 12 weeks after the start of therapy (ISH 0). Therapy with Ixekizumab is a promising therapy option for patients with Hidradenitis suppurativa. Further studies on the larger patient population would be desirable to further investigate the efficacy in this indication.

7. Ixekizumab in hidradenitis suppurativa: a case report in a psoriatic patient

Odorici G, Pellacani G, Conti A.

G Ital Dermatol Venereol. 2019 Jan 9

8. Severe refractory hidradenitis suppurativa: Treatment with ixekizumab, two case reports

Cotter C.; Tobin A.M.; O'Connor R.; Gallagher C.; Connolly M.

British Journal of Dermatology. Conference: 98th Annual Meeting of the British Association of Dermatologists, BAD 2018. United Kingdom. 179 (Supplement 1) (pp 70), 2018

Abstract: Hidradenitis suppurativa (HS) is a recurrent, chronic inflammatory skin disease. Evidences suggest immune dysregulation is implicated in the pathogenesis of HS. Biologics offer a promising nonsurgical approach in HS. Increased expression of IL-17 has been described in HS lesions and increased IL- 17 mRNA has been reported in perilesional skin of HS patients. In addition, increased serum levels of IL-17 have been recorded in patients with HS, nominating IL-17 as a potential therapeutic target. Ixekizumab is an interleukin IL- 17A antagonist approved for the treatment of adults with moderate-to-severe psoriasis. We report two cases of treatment of patients with severe refractory HS with the IL-17 inhibitor ixekizumab. The first case we report is 42-year-old woman with severe refractory HS. Previous therapies included ustekinumab, adalimumab, anakinra, infliximab, fumaderm and prolonged courses of multiple antimicrobial therapies. The patient had successfully discontinued smoking. Prior to commencing treatment, clinically the patient had Hurley stage III active disease in groin and right axilla. Her pain score was 5/10. She suffered from low mood and suicidal ideation. She was commenced on Ixekizumab at recommended psoriasis dosing. On the most recent review; the patient described subjective improvement. Clinically, there was also a marked improvement in the groin, and the axilla with absence of suppuration and decreased swelling. Pain has not improved. The patient has not experienced any side-effects apart from a headache in the initial period which has resolved. The second case is that of a 34-year-old woman with a diagnosis of severe refractory HS and Crohn disease. Previous treatments included surgery ustekinumab, adalimumab, infliximab and prolonged courses of antibiotics. She is an occasional smoker. Prior to commencing treatment, the patient had Hurley stage III disease in the groin. Pain was well controlled with analgesia. Following the initiation of ixekizumab at recommended psoriasis dosing, subjectively there has been an improvement in disease severity with reduced swelling in the vulval area and mons pubis. Clinically, there is ongoing disease in the groin and remains Hurley stage III but pain is well controlled. The patient has not experienced any deterioration in her Crohn symptoms. These two cases of the use of the IL- 17 inhibitor ixekizumab in severe refractory HS are significant, both patients report improvement and neither suffered significant side-effects. In particular, one patient had a diagnosis of Crohn disease and has tolerated the medication. To date, there has only been 1 report of the use of IL-17 inhibitors in HS. This could be a useful therapy in patients with severe refractory HS.

Esperamos que esta información le sea de utilidad. No dude en contactarnos de nuevo si requiere futura asistencia.

Referencias

1Taltz [summary of product characteristics]. Eli Lilly and Company (Ireland) Limited, Ireland

Está accediendo a contenido restringido.

Taltz® (ixekizumab) en hidradenitis supurativa